Lupaka Applies for Warrant Extension GlobeNewswire October 10, 2025 VANCOUVER, British Columbia, Oct. 10, 2025 (GLOBE NEWSWIRE) — Lupaka Gold Corp. (“Lupaka” or the “Company“) (TSX-V: LPK, FRA: LQP) announces that the Company intends to amend the terms of 2,000,000 outstanding common share purchase warrants of the Company (the “Warrants“) that are set to expire […]
On this World Mental Health Day, I encourage all Canadians to treat their mental health with the same importance they give their physical health. During my Mental Health Learning and Listening Tour, I met with Canadians who are redefining mental health and making a tangible difference across the country. They are taking action to foster
EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) — Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics' dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis (DM). According to Spherix Global Insights' latest Market Dynamix(TM): Idiopathic Inflammatory Myopathies (US) service, physicians view brepocitinib as a leading pipeline candidate to deliver on the most
(NASDAQ:FLYE), SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors of Fly-E Group, Inc. (NASDAQ: FLYE). The lawsuit seeks to recover losses on behalf of investors who purchased or acquired the Company's securities between July 15, 2025 and August 14,
Johnson Fistel Announces Class Action Lawsuit Against Fly-E Group, Inc. (FLYE) on Behalf of Investors GlobeNewswire October 10, 2025 SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors of Fly-E Group, Inc. (NASDAQ: FLYE). The lawsuit seeks to recover losses
Priovant's Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch Physician sentiment captured in Spherix Global Insights' research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across the broader IIM spectrum. GlobeNewswire October 10, 2025 EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) — Rheumatologists are eagerly anticipating the
XData Group, a European software development company specialising in digital banking solutions, has been named one of the winners of TechRound's SaaS66 2025 – an annual ranking that highlights the most promising SaaS innovators across the UK and Europe. https://mma.prnewswire.com/media/2793451/XData_Group_Photo.jpg XData Group was created to help financial institutions overcome the complexity of launching and scaling
NEW YORK CITY, NY / ACCESS Newswire / October 10, 2025 / NEW YORK, NY / ACCESS Newswire / October 10, 2025 / If you suffered a loss on your LifeMD, Inc. (NASDAQ:LFMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=171703&wire=1&utm_campaign=16
(NASDAQ:APM), $2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering GlobeNewswire October 10, 2025 $2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a